This multicenter study evaluates a full-situational awareness robotic bronchoscopy system combined with CBCT-based multimodal image fusion for diagnosing lung nodules in people living with HIV (PLWH). Lung nodules are small lesions that may be benign or cancerous. In PLWH, accurate diagnosis is especially important but challenging. In this study, participants will be assigned to one of two groups: * Experimental group: Robotic bronchoscopy with real-time full-situational awareness and CBCT image fusion; * Control group: Electromagnetic navigation-guided bronchoscopy combined with radial endobronchial ultrasound (EBUS). In both groups, rapid on-site cytologic evaluation (ROSE) will be performed to confirm tissue adequacy. For participants confirmed to have lung cancer and meeting safety criteria, an exploratory transbronchial cryoablation will be performed during the same procedure. The study aims to compare diagnostic accuracy and safety between the two approaches and to explore the feasibility of immediate cryoablation for early-stage lung cancer in PLWH.
Background Lung cancer is a leading cause of cancer mortality worldwide. Early detection and differentiation of pulmonary nodules are critical for survival. In people living with HIV (PLWH), pulmonary nodules carry a higher risk of malignancy, yet percutaneous biopsy is often contraindicated due to coagulation abnormalities or immunosuppression, and conventional bronchoscopy yields variable diagnostic rates (30%-70%) for peripheral nodules ≤3 cm. Electromagnetic navigation bronchoscopy (ENB) improves accessibility but lacks real-time intraoperative image feedback, while cone-beam CT (CBCT) provides intraoperative 3D imaging without dynamic fusion to robotic navigation. Existing robotic bronchoscopes improve stability but have limited distal fine control in complex airways. Preclinical and early clinical data suggest that full-situational awareness bronchoscopic robots (FSABR) integrated with CBCT-based multimodal image fusion can construct a dynamically updated 3D lung model, compensate for respiratory-induced target displacement, and improve tool-in-lesion accuracy and biopsy yield. However, clinical evidence-especially in PLWH-remains lacking. Study Design This is a prospective, multicenter, randomized (1:1), open-label, parallel-group controlled trial conducted at Shanghai Public Health Clinical Center and collaborating centers. Eligible PLWH with pulmonary nodules ≤3 cm (malignant risk ≥50% by CT) will be randomly assigned to: * Experimental arm: FSABR with CBCT-based multimodal image fusion guidance for targeted biopsy; * Control arm: ENB-guided bronchoscopy with radial endobronchial ultrasound (r-EBUS) localization for targeted biopsy. In both arms, rapid on-site evaluation (ROSE) will be performed to confirm specimen adequacy. For participants with ROSE-confirmed malignancy meeting predefined anatomic and clinical safety criteria, exploratory transbronchial cryoablation will be performed during the same procedure. This therapeutic component is hypothesis-generating only. Procedures Peripheral nodules will be localized by intraoperative imaging (CBCT in the experimental arm; r-EBUS in the control arm). Targeted biopsy will be performed using a 1.1-mm cryoprobe (typically 3 freeze-thaw cycles or until adequate tissue is obtained). Cryoablation (3 cycles × 12 min) will be attempted only in ROSE-positive patients with early-stage peripheral lung cancer deemed suitable by the operator. Follow-up includes chest CT at post-procedure day 1 and month 1 for all patients, and additional serial CT at 3, 6, 12, and 24 months for patients undergoing cryoablation, together with HIV virologic monitoring (viral load and CD4 count). Objectives The primary objective is to compare the diagnostic yield (proportion of cases with a definitive benign or malignant histocytologic diagnosis) between the FSABR-CBCT arm and the ENB-r-EBUS arm. Secondary objectives include: tool-in-lesion rate, nodule visualization rate, ROSE adequacy, specimen quality, procedural times, safety (pneumothorax, bleeding, infection, HIV-related events), and feasibility/safety of same-session cryoablation. Sensitivity, specificity, positive and negative predictive values, and accuracy for malignancy will also be calculated using final histopathology or 6-12-month imaging follow-up as reference standard. This study is expected to provide evidence on the clinical utility of full-situational awareness robotic bronchoscopy with intraoperative CBCT fusion in a vulnerable population and to explore the feasibility of a "diagnose-and-treat" strategy for early lung cancer in PLWH.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
100
Participants undergo peripheral pulmonary nodule biopsy using a full-situational awareness bronchoscopic robot. Intraoperative cone-beam CT (CBCT) and multimodal image fusion are used for real-time navigation. ROSE is performed. If ROSE confirms malignancy and safety criteria are met, exploratory transbronchial cryoablation is done in the same session. If robotic navigation fails to obtain a definitive diagnosis, percutaneous transthoracic needle biopsy (PTNB) may be used as rescue.
Participants undergo peripheral pulmonary nodule biopsy using electromagnetic navigation bronchoscopy (ENB) with radial endobronchial ultrasound (r-EBUS) localization. ROSE is performed. If ROSE confirms malignancy and safety criteria are met, exploratory transbronchial cryoablation is done in the same session. If ENB-rEBUS fails to obtain a definitive diagnosis, percutaneous transthoracic needle biopsy (PTNB) may be used as rescue.
Diagnostic Yield
Proportion of participants from whom a definitive benign or malignant diagnosis is established by histopathology (tissue or ROSE-guided cytology) or, for presumed benign lesions, by stable imaging on 6- to 12-month follow-up. Cases with inadequate specimen or indeterminate pathology are counted in the denominator but not as diagnostic successes.
Time frame: From initial bronchoscopic biopsy through final histopathologic or 12-month imaging confirmation
Tool-in-Lesion Rate
Proportion of cases in which the biopsy/cryoprobe tip is confirmed to be within or in direct contact with the target pulmonary nodule by intraoperative imaging (CBCT in the experimental arm; r-EBUS in the control arm).
Time frame: Intraoperative (at time of biopsy attempt)
Nodule Visualization Rate
Proportion of target nodules clearly visualized intraoperatively: by CBCT in the robotic arm; by "bull's-eye" or "snowstorm" sign on r-EBUS in the control arm.
Time frame: Intraoperative
ROSE Adequacy
Proportion of first biopsy specimens judged as adequate (presence of atypical/suspicious/malignant cells or definitive benign elements) by rapid on-site cytologic evaluation (ROSE).
Time frame: Intraoperative
Qualified Cryobiopsy Specimen Rate
Proportion of cryobiopsy specimens meeting predefined quality criteria (length ≥5 mm and containing ≥3 cohesive cell clusters).
Time frame: Intraoperative (immediate pathologic assessment)
Cryoablation Success (Exploratory)
Among ROSE-confirmed malignant cases deemed eligible for ablation, proportion in which the cryoprobe is successfully positioned and 3 ablation cycles (12 minutes each) are completed without premature termination due to complication or technical failure.
Time frame: Intraoperative
Complete / Partial Ablation Response Rate
Proportion of cryoablated lesions showing complete absorption, fibrosis, or ≥50% size reduction on follow-up HRCT at 6 and 12 months. Assessed only in patients who underwent cryoablation.
Time frame: 6 months and 12 months post-procedure
Procedure Time
Time from bronchoscope insertion to removal (total), and separately recorded: navigation time, biopsy time, and cryoablation time (if performed).
Time frame: Intraoperative
Safety - Overall Adverse Event Rate
Incidence of pneumothorax, bleeding (graded mild/moderate/severe), pneumonia/fever, air embolism, and HIV-related events (viral load rebound \>50 copies/mL or CD4 drop). Severity and relationship to procedure will be assessed per protocol.
Time frame: From procedure through 30 days post-procedure (through 24 months for ablated patients regarding delayed complications)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.